Although gender and oestrogen treatment influence production of the vasorelaxant, NO, their influence on factors downstream in the NO signal-transduction pathway, specifically protein kinase G (PKG), remains unknown. We aimed to study the influence of sex hormones on PKG, along with the endothelial modulation of these effects, in rat thoracic aortic rings in two separate groups, control male and female rats and ovariectomized female rats after treatment with oestrogen or vehicle. Vessel preparations were preconstricted with phenylephrine (0.1 µM). Constrictions were greater in male than female aortas. This differential effect was attenuated by endothelium removal, addition of the guanylate cyclase inhibitor
INTRODUCTION
The cardioprotective effects of oestrogen have been attributed to a diverse range of biological effects, including beneficial alterations in lipid profiles, vascular cell growth and atherogenesis [1] . Oestrogen also modulates blood vessel reactivity and vasomotor tone, primarily mediated by its effects on the potent vasodilator NO [2, 3] . This has been suggested by observed genderspecific differences in NO release and vasorelaxation responses [4] [5] [6] . NO release from rat and rabbit aortic rings is greater in female than in male animals [5] . In the primate model, oestrogen-replete females demonstrate greater acetylcholine-induced, NO-mediated, coronary artery vasodilation, than males or oestrogen-depleted females [4] . This is supported by in vivo studies in humans, where women have greater NO-mediated endothelial-dependent vasodilation compared with men [6] . Furthermore, in the animal model, oestrogen treatment has been shown to modulate NO, increasing the amount of mRNAs for nitric oxide synthase (NOS) isozymes, suggesting that the increases in NOS activity result from enzyme induction [7] . This is supported by a diverse range of studies also showing increased expression of NOS in animal studies [7] [8] [9] [10] and in human studies [11, 12] , including those in cultured human aortic endothelial cells, where oestrogen treatment increases NO production accompanied by increased NOS protein [11] .
NO activates soluble guanylate cyclase to produce cGMP [13] . cGMP in turn induces relaxation of vascular smooth muscle by mechanisms which predominantly involve activation of the primary effector molecule, protein kinase G (PKG). In turn, PKG induces phosphorylation of key proteins in the contraction\ relaxation process, such as the Na# + \Ca# + exchange, the sarcoplasmic reticulum Ca# + -ATPase, the sarcolemmal Ca# + \Mg# + -ATPase, the Ca# + \K + myosin light-chain kinase and myosin light-chain phosphatase [14] .
While oestrogen treatment appears to relax vascular smooth muscle by NO-mediated production of cGMP [10] , the effects of gender and oestrogen treatment on the primary downstream effector molecule of the NOcGMP signalling pathway, PKG, remain unclear. Recently, it has been shown that oestrogen increased PKG immunoreactivity and activity in rat uterine smooth muscle, an effect that was negated by progesterone [15] . Furthermore, these effects appeared to be independent of the hormonal regulation of NO and cGMP [15] . However, the influence of gender or oestrogen treatment on downstream events, specifically PKG, in this NOcGMP-PKG signal transduction pathway, is yet to be elucidated in vascular smooth muscle.
There are two known PKG isoforms in vascular smooth muscle, PKG type 1α and 1β, present in approximately equal proportions in bovine, human and rat aorta [16, 17] . The aim of the present study was to characterize the effect of gender and oestrogen treatment on vascular relaxation mediated by these PKG isoforms. This was carried out in isolated segments of rat aorta, using the newly developed cell permeable cGMP analogues, which activate PKG type 1 with little or no effect on PKG type 2 [18, 19] and protein kinase A (PKA) [20, 21] . The analogues used were β-phenyl-1-N#-ethano-8-bromocGMP (8-Br-PET-cGMP), which activates both 1α (K a l 13 nM) and 1β (K a l 9 nM) isoforms, and 8-(2-aminophenylthio)cGMP (8-APT-cGMP), which has 200-fold greater selectivity for type 1α (K a l 7 nM) compared with 1β (K a l 1370 nM) [17] .
METHODS

Animals
Experiments were approved by the Monash Medical Centre (Melbourne, Australia) animal ethics committee. Two groups of experiments were performed on SpragueDawley rats. The first experiments were conducted on healthy untreated male and female rats (200-260 g), with the second experiments being performed on oestrogentreated female rats. Although of similar weights, male rats averaged 238p3 g and females were 240p2 g, this equates to a 2 week age difference between the two groups. Treated female rats, weighing 150-180 g at baseline (200-280 g at the time of the vessel experiments), were anaesthetized with sodium methohexitone and sodium amylobarbitone (20 mg\kg intraperitoneally and 60 mg\kg intraperitoneally respectively). The animals were assigned to one of three treatment groups. In groups 1 and 2 the ovaries were ligated and removed, whereas in group 3 the animals were sham-operated. Animals were then allowed to recover for 21 days with food and water ad lib. Following recovery of the ovariectomized rats, an osmotic mini pump (Alzet Corporation, Cupertino, CA, U.S.A) was implanted subcutaneously at the back of the neck, where it remained for 14 days (until the animal was sacrificed). Group 1 rats received 17β-oestradiol (0.01 µg\100 g body weight\h), group 2 rats received vehicle (propylene glycol), whereas group 3 shamoperated animals were not treated. At the time of death, body weight and uterine weight were recorded, and plasma collected for measurement of 17β-oestradiol, which was measured by standard automated sensitive immunoassay ACS180 (Diagnostic Products Corp., Los Angeles, CA, U.S.A.). Treated animals were excluded if 17β-oestradiol levels were 20 pM in the vehicle-treated group (group 2) or 400 pM in the 17β-oestradioltreated group (group 1).
Tissue preparation
The rats were killed by decapitation. The thoracic aorta was removed, fat and connective tissue was dissected away, and the remaining vessel cut into ring segments (4 mm in length). Each ring was then placed in an organ bath containing 1.0 ml of physiological salt solution (pH 7.4) of the following composition : 118 mM NaCl, 4.7 mM KCl, 1.03 mM KH
.067 mM EDTA and 0.14 mM ascorbic acid. Where necessary, the endothelium was removed by gentle rubbing of the luminal surface with a stainless steel rod. Rings were mounted between two stainless steel hooks through the lumen, with the lower hook connected to a tissue holder and the upper hook to an isometric forcedisplacement transducer. Rings were washed thoroughly by replacing the physiological salt solution repeatedly, and were then allowed to equilibrate for a period of 45 min under 2 g of resting tension. Supply reservoirs and organ baths were maintained at 37 mC and were gassed with O # \CO # (19 : 1).
Tissue viability assessment
Following the 45 min equilibration period the viability of the tissues was assessed. Tissues which failed to produce a 0.5 g increase in tension to phenylephrine (0.1 µM) were rejected. In those experiments using endotheliumdenuded aortas, successful removal of endothelial cells was confirmed by the inability of acetylcholine (1 µM) to induce relaxation in the presence of phenylephrine. The tissue-bathing solution was replaced repeatedly with fresh drug-free physiological salt solution until a stable baseline tension was achieved. The tension was then readjusted to 2 g.
Vasorelaxation studies
Following assessment of tissue viability, tissues were allowed to equilibrate for a further 45 min, during which time additional drugs were added where required, remaining present from 45 min. These included the NOS inhibitor, N G -monomethyl-L-arginine (L-NMMA ; 100 µM) and the guanylate cyclase inhibitor, 1H-
All vessel preparations were then constricted with phenylephrine (0.1µM), which was the concentration inducing 85 % maximal constriction based on full phenylephrine concentration-response curves performed in preliminary experiments in endothelium-denuded aortic rings from male and female rats. After the phenylephrine response had reached a stable plateau, either 8-Br-PET-cGMP or 8-APT-cGMP (1-300 µM) were added in a cumulative fashion. For both cGMP analogues (added cumulatively over a 2 h period) concurrent control experiments with vehicle were performed. The timing of the relaxation curves was based on manufacturer data on activation velocities of these analogues. Specifically, cGMP analogues are bulkier in molecular design and, in addition, carry a negative charge which makes them less hydrophobic and membrane permeable, resulting in a slower activation velocity as compared with NO, which crosses cellular membranes easily due to its small size and its high lipophilicity [22] . Therefore 20 min equilibration times were allowed between subsequent additions of 8-Br-PET-cGMP or 8-APT-cGMP. The klog EC &! was defined as the klog of the concentration of 8-Br-PETcGMP or 8-APT-cGMP required to reduce the phenylephrine constriction to 50 % of the initial constriction.
Drugs and materials
Acetylcholine perchlorate, L-NMMA and phenylephrine hydrochloride were obtained from Sigma, ODQ was supplied by Tocris Cookson Ltd (Langford, Bristol, U.K.) and 8-APT-cGMP and 8-Br-PET-cGMP were from Biolog Life Science Institute (Bremen, Germany). ODQ was initially dissolved in DMSO (the final concentration of DMSO did not exceed 1 %).
Statistical analysis
All values are given as meanspS.E.M., and n indicates the number of observations. Differences between curves were analysed using a repeated measures two-way ANOVA. The differences between klogEC &! values and phenylephrine constrictions were analysed using Student's t test. P values 0.05 were considered to be significant. The GBSTAT statistical package (Dynamic Microsystems, Silver Spring, MD, U.S.A.) was used in all calculations. Although multiple rings were obtained from one rat, each ring was used for a different drug group.
RESULTS
Phenylephrine constriction
The size of the constriction produced by phenylephrine (0.1 µM), in g of tension generated, was greater in aortas from male compared with female rats (Table 1 ). However, All vessels were preconstricted with phenylephrine (0.1 µM). Cumulative concentration-response curves to 8-APT-cGMP were conducted in endotheliumdenuded aortas (a), or in endothelium-intact aortas in the presence of 1 µM ODQ (b) or 100 µM L-NMMA (c). Responses are expressed as a percentage of initial phenylephrine induced constriction. Each point represents the meanpS.E.M. (n l 9-12). A significant difference (P 0.05) between the two curves in each panel was found in (c) only using repeated measures two-way ANOVA. 
Effect of cGMP analogues
The cell-permeable cGMP analogues 8-Br-PET-cGMP and 8-APT-cGMP (1-300 µM) produced a concentration-dependent relaxation of endothelium intact aortic rings constricted with phenylephrine 0.1µM ( The effects of gender on vasorelaxant responses to 8-Br-PET-cGMP and 8-APT-cGMP were studied. Both analogues were more potent in aortas from males than females (Table 1 and Figure 1) . In further experiments, the involvement of the vascular endothelium and endothelial NO on the relaxation produced by 8-APTcGMP was evaluated in aortic rings from both male and female rats (Table 1 and Figure 2 ). The gender differential vasorelaxant effect of 8-APT-cGMP on endotheliumintact aortic rings in males compared with female rats was negated by endothelium removal and addition of the guanylate cyclase inhibitor, ODQ (1 µM), but not by the NOS inhibitor, L-NMMA (100µM), which had no appreciable effect on vasorelaxation in males ( Figure 2 and Table 1 ).
Effect of 17β-oestradiol
17β-Oestradiol concentrations were higher in oestrogentreated compared with vehicle-treated ovariectomized rats. In addition, clinical effects of oestrogen therapy were evident, with the body weight of oestrogen-treated ovariectomized rats being significantly lower than that of vehicle-treated rats at the time of death. Furthermore, the uterine weight was significantly reduced in vehicletreated compared with oestrogen-treated ovariectomized rats (Table 2 ). Cumulative concentration-response curves to 8-APT-cGMP were conducted in the presence of ODQ (1 µM) in aortas from sham-operated ( ) or ovariectomized rats treated with either oestrogen ($) or its vehicle (#). Responses are expressed as a percentage of initial phenylephrine-induced constriction. Each point represents the meanpS.E.M. (n l 7-11). There was no significant difference between the relaxant responses to 8-APT-cGMP from any of the three treatment groups.
As the effects of oestrogen on the upregulation of NOS have been well established [7] [8] [9] [10] [11] [12] , and the focus of these studies was to analyse effects of oestrogen on PKG, all aortic rings in this substudy were pretreated with ODQ to overcome the differential production of endogenous NO between the groups. In the presence of 1 µM ODQ, there was no significant difference (P 0.05, Student's t test) between the size of the constriction produced by 0.1 µM phenylephrine in isolated aortic rings from sham-ovariectomized (2.30p0.05 g), ovariectomized (2.00p0.18 g) or ovariectomized oestrogen-treated rats (2.23p0.08 g), nor was there any difference in the relaxation response to the cell-permeable cGMP analogue, 8-APT-cGMP, between the three groups ( Figure 3) .
DISCUSSION
Oestrogen appears to modulate vascular reactivity and tone [2, 3] , with female blood vessels having greater basal NO release compared with corresponding male vessels [6, 23, 24] . Furthermore, female blood vessels relax more readily to the NO-mediated endothelium-dependent vasodilator acetylcholine than male blood vessels [6, [25] [26] [27] . Results of the present study in rats are consistent with these previous findings, since constriction produced by phenylephrine (0.1 µM) was greater in aortas from male compared with female rats. This difference in phenylephrine responses between the sexes was abolished by endothelium removal, by the guanylate cyclase inhibitor ODQ and by the NOS inhibitor L-NMMA (see Table 1 ), all of which increased the constriction proportionately more in females, supporting the conclusion that the factor responsible for this observed gender difference was NO.
The present study was carried out using cell-permeable cGMP analogues, which selectively activate PKG type 1 with little or no effect on PKG type 2 [18, 19] and PKA [20, 21] , including 8-Br-PET-cGMP which activates both PKG 1α (K a l 13 nM) and type 1β (K a l 9 nM), and 8-APT-cGMP which is selective for type 1α (K a l 7 nM) over 1β (K a l 1370 nM) by a factor of 200 [17] . In this study, both of these cGMP analogues relaxed rat aortas, with 8-Br-PET-cGMP more potent than 8-APT-cGMP. The potency ratio for 8-Br-PET-cGMP\8-APT-cGMP in aortas from male rats was 0.43 and in female rats 0.39. In isolated enzyme studies, the potency for 8-Br-PETcGMP\8-APT-cGMP for PKG 1α is k0.26 and for PKG 1β 2.19 [17] . In the present study, the potency ratio for 8-Br-PET-cGMP\8-APT-cGMP is most similar to that of PKG 1α. This is also in line with our previous findings in rat aortas [28] and a previous study in pig coronary artery [17] . These findings support the suggestion that PKG 1α is the primary subtype involved in vasorelaxation. At present, the lack of specific activators of PKG type 1β makes it difficult to determine the role of this isoform in vasorelaxation.
Previous studies [25, 26] have looked at the effect of NO donors, including sodium nitroprusside, on vasorelaxation and generally found no difference in vasodilator responses between genders. However, this issue is not straightforward, with some studies noting gender differences in relaxation induced by an NO donor, with vasodilation being more pronounced in female than in male rats [27] . While others have demonstrated no gender differences in vasorelaxation responses to NO donors, many were in endothelially denuded preparations, bypassing any endothelial cGMP-PKG pathway effects [26] . Furthermore, NO donors involve other upstream NO pathway components and do not activate PKG directly, potentially obscuring more subtle specific modulation of PKG by oestrogen, when activating the entire NO-cGMP-PKG pathway. Finally, NO donors also have direct effects independent of PKG. All of these factors make it difficult to extrapolate to PKG-mediated vasorelaxation responses based on vasodilation responses to NO donors. In the present study, specific PKGmediated vasorelaxation was studied with both of these analogues, demonstrating consistently greater relaxtion in aortas from male than female rats. This difference was negated by endothelium removal and addition of nonspecific ODQ, but not of L-NMMA. We speculate that one explanation that could account for the gender differences in PKG-mediated vasorelaxation is that, in males, endothelial pathways other than NO may regulate vasorelaxation mediated by PKG. These pathways may be blocked by ODQ, which is documented to not only inhibit guanylate cyclase but also other haemoproteins, including cytochrome P450, as well as other endothelial biochemical pathways [29] . However, blockade of NOS with the more specific L-NMMA does not affect the PKG-mediated vasorelaxation in males as it does in females, suggesting that PKG regulation may be more dependent on NO regulation in female than in male rats.
Based on our original hypothesis that oestrogen may upregulate PKG in the vasculature, as it does in the uterus, we investigated the influence of 17β-oestradiol on PKG-mediated relaxation to 8-APT-cGMP. These experiments were completed in sham-, vehicle-and oestrogen-treated ovariectomized rats. Both ovariectomy and oestradiol treatment appeared effective, based on plasma 17β-oestradiol levels and changes in both uterine and body weights (see Table 2 ). There was no difference in 8-APT-cGMP-mediated relaxation in any of these three treatment groups. Although it was possible that differences in endogenous NO production obscured direct PKG effects, the vasorelaxation studies were conducted in the presence of the guanylate cyclase inhibitor ODQ, limiting the variations in upstream NO from directly affecting the vasodilator response through PKG. Thus it appears that PKG in female vascular tissue is not directly subjected to oestrogen modulation as we had originally hypothesized, as has been previously shown with uterine PKG [15] . These results are, however, consistent with previous literature [25, 26] , which showed that activation of the guanylate cyclase-PKG signal transduction pathway is unaffected by oestrogen status. These findings also suggest that oestrogen does not contribute to the observed gender difference in PKGmediated vasorelaxation, since oestrogen-replete female rats with upregulated NO may potentially have reciprocal down-regulation of PKG. However, neither an upregulation nor a downregulation of PKG was observed in the present study, making this unlikely.
In conclusion, these findings demonstrate that in the presence of the endothelium female rats have greater basal NO production compared with males, resulting in a reduced constrictor response to phenylephrine. PKG 1α appears to be the primary PKG subtype responsible for vasorelaxation produced by activation of the NOcGMP-PKG signal transduction pathway in the rat aortas. It was also noted that the relaxant responses to PKG activation were greater in aortas from male rats, when compared with female rats, and that this differential response, although endothelial-dependent, was not negated by blockade of NOS, suggesting alternative influences of PKG in males. In contrast with the uterine PKG, the hormonal milieu in females does not appear to directly influence vascular PKG with neither oestrogen withdrawal, nor chronic oestrogen treatment of ovariectomized rats, affecting PKG-mediated vasorelaxation. Therefore factors other than oestrogen appear to be responsible for the gender differences in PKG activity seen in the present study.
